MEDICAL INFORMATION FOR HEALTH CARE PROFESSIONALS

Go to other sections:

Treatment  / Medication Fact Sheets


STAVUDINE (d4T)

Other names: Zerit®

WHY is this medication prescribed ?

Stavudine is an antiretroviral medication which slows the progression of HIV infection. It belongs to a class of drugs called nucleoside analogues. Stavudine interferes with the replication of the HIV virus by blocking the reverse transcriptase enzyme. The HIV virus needs this enzyme to replicate. Stavudine slows down the replication of the HIV virus and may therefore slow the progression of HIV disease. Stavudine is used in combination with other antiretroviral agents. It may be used for patients who do not tolerate or who no longer are benefiting from zidovudine therapy. Stavudine does not cure HIV nor does it prevent HIV transmission.

HOW should this drug be taken ?

The dose of stavudine is based on your body weight. It is usually given twice daily. The dose may range from 15-40 mg twice daily, depending upon your body weight. Stavudine is supplied as capsules which should be swallowed whole. The capsules are available in 15mg, 20mg, 30mg and 40 mg strengths. The capsules can be taken with or without food.

What should you do if you FORGET a dose ?

If you miss a dose of stavudine, take it as soon as possible. However, if it is time for your next dose, do not double the dose, just carry on with your regular schedule.

What ADVERSE EFFECTS can this drug cause ? What should you do about them?

Stavudine can cause peripheral neuropathy (problems with impluse transmission in the nerves). Symptoms may include tingling, burning, pain, or numbness in the hands and feet. Stavudine may also cause pancreatitis (inflammation of the pancreas). Symptoms can include abdominal pain, nausea, and vomiting. These symptoms are reversible if recognized quickly and the drug is discontinued, or if the dose is reduced. If you develop any of these symptoms, please call the clinic.

Other adverse effects include: nausea, vomiting, abdominal pain, diarrhea, and difficulty sleeping. If these effects occur and are bothersome, please call the clinic or discuss them at your next visit.

In rare cases, stavudine can lower white blood cells (needed to help fight infection), or cause abnormalities in blood tests of liver function. To monitor for these side effects, blood tests must be done regularly.

IT IS IMPORTANT THAT YOU KEEP YOUR DOCTOR AND LABORATORY APPOINTMENTS, SO THAT YOUR PROGRESS CAN BE ASSESSED REGULARLY.

IF YOU ARE EXPERIENCING ANY ADVERSE EFFECTS, PLEASE DISCUSS THEM WITH YOUR HEALTH CARE TEAM.

What other PRECAUTIONS should you follow while using this drug ?

This medication can interact with other drugs. It is important that your physician or pharmacist knows about other drugs you are taking, even medications you can buy without a prescription

Stavudine is generally not given in combination with zidovudine. Stavudine may decrease the efficacy of zidovudine.

Other medications which also cause neuropathy may increase your risk of developing neuropathy, when combined with stavudine. Examples include didanosine (ddI), and zalcitabine (ddC). Discuss this with your physician if this is a concern.

The safety of stavudine has not been established during pregnancy or breastfeeding. Please discuss this with your doctor or pharmacist if this is a concern.

How should this medication be STORED ?

Stavudine should be stored in a cool (15-30 0C) dry place, well out of the reach of children. Do not store in your bathroom or kitchen, as heat and moisture may cause the medication to lose potency.

IF YOU HAVE ANY QUESTIONS OR CONCERNS ABOUT THIS MEDICATION, PLEASE DISCUSS THEM WITH YOUR NURSE, PHARMACIST, OR PHYSICIAN.

PLEASE WRITE DOWN YOUR QUESTIONS OR CONCERNS TO ENSURE THEY ARE ADDRESSED.

A pharmacist at ___________________ is available to answer questions.

The telephone number is ___________.  Please ask for ____________________.

Adapted from the Zerit product monograph, Bristol-Myers-Squibb, 1996. Edited by the CSHP Ontario Branch Professional Specialty Group in HIV Disease, in conjunction with the HIV/AIDS Outpatient Network of Ontario Coordinators Sub-Group, 1997.